Bristol-Myers Squibb Co.

NYSE:BMY   12:52:04 PM EDT
77.37
+0.13 (+0.17%)
Products, Strategic Combinations, Restructuring / Reorganization

Evotec And Bristol Myers Squibb Extend And Expand Strategic Partnership

Published: 05/10/2022 14:38 GMT
Bristol-Myers Squibb Co. (BMY) - Dgap-adhoc: Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership.
Dgap-adhoc: Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership.
Evotec Se - Aim of Eight-year Extension is to Develop a Broad Pipeline of Molecular Glue Degraders Which Are Small, Drug-like Compounds.
Evotec Se - Evotec's Proprietary Evopanomics and Evopanhunter Platforms As Well As Ai/ml-based Drug Discovery and Development Platforms Will Be Leveraged.
Evotec Se - Receives an Upfront Payment of $ 200 M and Expects to Obtain Further Performance-based, Near-term and Programme-based Milestone Payments, Resulting in a Deal Potential of $ 5 Bn With Additional Tiered Royalties on Product Sales.